An FDA advisory panel on Bristol Myers Squibb Opdivo and Merck Keytruda will examine if PD-L1 tumor expression should limit ...

Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the European Medicines Agency's ...

In a news packed morning, Japanese drugmaker Astellas Pharma (TYO: 4503) today revealed two regulatory approvals.

MINNEAPOLIS, Sept. 24, 2024 (GLOBE NEWSWIRE) -- (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today ...

AEMD READ THE FULL AEMD RESEARCH REPORT AEMD basket oncology trial, patient enrollment process We participated in a ...

Shares in Anixa Biosciences rose after the company outlined plans for a Phase 2 study of its breast cancer vaccine. Shares were recently up 5% at $3.39.

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced its strategic plan for a Phase 2 study for ...

First signs of clinical benefit in adjuvant head and neck cancer reported at AACR 2024, paved the way for the start of Phase II part of randomized Phase I/II clinical trial in Q2 2024 – Median ...

Announces focus on therapeutic approach; resulting in a faster and more cost-effective path to approval SAN JOSE, Calif., Sept. 24, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Compan ...

"If patients with low or no PD-L1 expression are not expected to benefit based on the available data, then administering anti ...

We recently published a list of the 13 Most Undervalued Blue Chip Stocks To Buy According To Analysts. In this article, we ...